Table 5.
Variables | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
VZV + (n = 6) | VZV−(n = 312) | p Value | ORs | 95%CI | p Value | |
Gender, female, n (%) | 6 (100.0) | 215 (68.9) | 0.183 | |||
Age, year, median (IQR) | 33 (31−41) | 41 (32−52) | 0.228 | |||
AIIRDs type, n (%) | ||||||
SLE | 3 (50.0) | 73 (23.4) | 0.150 | |||
RA | 1 (16.7) | 100 (32.1) | 0.669 | |||
SpA | 2 (33.3) | 48 (15.4) | 0.240 | |||
Disease duration, year, median (IQR) | 12 (2, 14) | 6 (2, 10) | 0.336 | |||
Medical history, n (%) | ||||||
Diabetes mellitus | 2 (33.3) | 8 (2.6) | 0.013 | 20.69 | 1.08−396.79 | 0.044 |
Chronic liver disease | 1 (16.7) | 10 (3.2) | 0.192 | |||
Chronic HBV infection | 2 (33.3) | 7 (2.2) | 0.010 | 24.34 | 1.27−466.74 | 0.034 |
Medications, n (%) | ||||||
Corticosteroid | 3 (50.0) | 101 (32.4) | 0.397 | |||
Hydroxychloroquine | 2 (33.3) | 127 (40.7) | 1.000 | |||
Immunosuppressive agents | 3 (50.0) | 149 (47.8) | 1.000 | |||
Mycophenolate mofetil | 3 (50.0) | 30 (9.6) | 0.016 | 40.61 | 3.33−496.15 | 0.004 |
Biological agents | 1 (16.7) | 85 (27.2) | 1.000 | |||
JAK inhibitor | 1 (16.7) | 7 (2.2) | 0.159 | |||
Prior history of Herpes Zoster, n (%) | 2 (3) | 110 (35.3) | 1.000 | |||
Get vaccination of Varicella zoster vaccine, n (%) | 0 (0.0) | 2 (0.6) | 1.000 | |||
Get vaccination of Herpes zoster vaccine, n (%) | 0 (0.0) | 4 (1.3) | 1.000 |
Abbreviations: AIIRDs, Autoimmune inflammatory rheumatic diseases; HBV, Hepatitis B virus; IQR, Interquartile Range; RA, Rheumatoid arthritis; SLE, Systemic lupus erythematosus; SpA, Spondyloarthritis.